Antiretroviral therapy dispensing for patients who are clinically stable

Achieving HIV treatment targets such as 95-95-95 will help control the HIV epidemic. Key to this is implementation of efficient models that optimise patient engagement. WHO recommend multi-month dispensing of antiretroviral therapy (ART) for up to six months for stable patients because of positive effects in reducing the burden on health systems and time and opportunity costs for patients. Six-month dispensing intervals through differentiated community-based models demonstrate non-inferiority to 3-month facility-collection models. In this issue of the Lancet Global Health, Risa Hoffman and colleagues add to this evidence by reporting on a pragmatic non-inferiority cluster randomised trial of facility-based multi-month dispensing in Malawi and Zambia (INTERVAL).